inclusion criteria: 1. male or female ≥18 years of age. 2. individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures. 3. individuals are willing and able to give an informed consent, prior to screening. 4. individuals must have completed vaccine priming, regardless of vaccine regimen. primary vaccination and previous booster scheme data will be annotated as patient history. 5. interval between last dose and current study dose of a minimum of 4 months and a maximum of 24 months (to optimize candidate participation). 6. healthy participants or participants with pre-existing medical conditions who are in a stable medical condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. 7. female participants are eligible to participate in the study if not pregnant, not breastfeeding, and at least 1 of the following criteria apply: * women of non-childbearing potential; * women of childbearing potential (wocbp) must have a negative urine pregnancy test prior to study vaccination. a confirmatory serum pregnancy test may be conducted at the investigator's discretion. they must be using a highly effective licensed method of birth control during the study, until 90 days after the study vaccination.

inclusion criteria: 1. male or female ≥18 years of age. 2. individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures. 3. individuals are willing and able to give an informed consent, prior to screening. 4. individuals must have completed vaccine priming, regardless of vaccine regimen. primary vaccination and previous booster scheme data will be annotated as patient history. 5. interval between last dose and current study dose of a minimum of 4 months and a maximum of 24 months (to optimize candidate participation). 6. healthy participants or participants with pre-existing medical conditions who are in a stable medical condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. 7. female participants are eligible to participate in the study if not pregnant, not breastfeeding, and at least 1 of the following criteria apply: * women of non-childbearing potential; * women of childbearing potential (wocbp) must have a negative urine pregnancy test prior to study vaccination. a confirmatory serum pregnancy test may be conducted at the investigator's discretion. they must be using a highly effective licensed method of birth control during the study, until 90 days after the study vaccination.

inclusion criteria: male or female ≥18 years of age. individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures. individuals are willing and able to give an informed consent, prior to screening. individuals must have completed vaccine priming, regardless of vaccine regimen. primary vaccination and previous booster scheme data will be annotated as patient history. interval between last dose and current study dose of a minimum of 4 months and a maximum of 24 months (to optimize candidate participation). healthy participants or participants with pre-existing medical conditions who are in a stable medical condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. female participants are eligible to participate in the study if not pregnant, not breastfeeding, and at least 1 of the following criteria apply: women of non-childbearing potential; women of childbearing potential (wocbp) must have a negative urine pregnancy test prior to study vaccination. a confirmatory serum pregnancy test may be conducted at the investigator's discretion. they must be using a highly effective licensed method of birth control during the study, until 90 days after the study vaccination.

inclusion criteria: male or female ≥18 years of age. individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures. individuals are willing and able to give an informed consent, prior to screening. individuals must have completed vaccine priming, regardless of vaccine regimen. primary vaccination and previous booster scheme data will be annotated as patient history. interval between last dose and current study dose of a minimum of 4 months and a maximum of 24 months (to optimize candidate participation). healthy participants or participants with pre-existing medical conditions who are in a stable medical condition. a stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment. female participants are eligible to participate in the study if not pregnant, not breastfeeding, and at least 1 of the following criteria apply: women of non-childbearing potential; women of childbearing potential (wocbp) must have a negative urine pregnancy test prior to study vaccination. a confirmatory serum pregnancy test may be conducted at the investigator's discretion. they must be using a highly effective licensed method of birth control during the study, until 90 days after the study vaccination.